JP2002520368A - プロスタグランジン製品 - Google Patents
プロスタグランジン製品Info
- Publication number
- JP2002520368A JP2002520368A JP2000559870A JP2000559870A JP2002520368A JP 2002520368 A JP2002520368 A JP 2002520368A JP 2000559870 A JP2000559870 A JP 2000559870A JP 2000559870 A JP2000559870 A JP 2000559870A JP 2002520368 A JP2002520368 A JP 2002520368A
- Authority
- JP
- Japan
- Prior art keywords
- cyclohexyl
- oxa
- pentanor
- chloro
- dihydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003180 prostaglandins Chemical class 0.000 title claims abstract description 60
- -1 polypropylene Polymers 0.000 claims abstract description 83
- 239000000203 mixture Substances 0.000 claims abstract description 75
- 239000004743 Polypropylene Substances 0.000 claims abstract description 48
- 229920001155 polypropylene Polymers 0.000 claims abstract description 48
- 239000002253 acid Substances 0.000 claims description 40
- 239000008389 polyethoxylated castor oil Substances 0.000 claims description 18
- 239000004359 castor oil Substances 0.000 claims description 10
- 235000019438 castor oil Nutrition 0.000 claims description 7
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 7
- 239000004094 surface-active agent Substances 0.000 claims description 7
- 230000000699 topical effect Effects 0.000 claims description 6
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 4
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- MKPLKVHSHYCHOC-JPVYXPJZSA-N propan-2-yl (e)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(e,3r)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoate Chemical compound CC(C)OC(=O)CCC\C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-JPVYXPJZSA-N 0.000 claims description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 2
- QKIUAMUSENSFQQ-UHFFFAOYSA-N dimethylazanide Chemical compound C[N-]C QKIUAMUSENSFQQ-UHFFFAOYSA-N 0.000 claims description 2
- 229960001160 latanoprost Drugs 0.000 claims description 2
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 claims description 2
- 239000008180 pharmaceutical surfactant Substances 0.000 claims description 2
- OCNSAYQJDKJOLH-AHTXBMBWSA-N propan-2-yl (z)-7-[(1r,2r,3r,5s)-2-[(e,3r)-4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(Cl)=C1 OCNSAYQJDKJOLH-AHTXBMBWSA-N 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 45
- 239000004698 Polyethylene Substances 0.000 abstract description 5
- 229920000573 polyethylene Polymers 0.000 abstract description 4
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 2
- 229940127557 pharmaceutical product Drugs 0.000 abstract description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- 150000001875 compounds Chemical class 0.000 description 16
- 229920001684 low density polyethylene Polymers 0.000 description 16
- 239000004702 low-density polyethylene Substances 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000011521 glass Substances 0.000 description 13
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 11
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 10
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 9
- 229930195725 Mannitol Natural products 0.000 description 9
- 239000000594 mannitol Substances 0.000 description 9
- 235000010355 mannitol Nutrition 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 229960000686 benzalkonium chloride Drugs 0.000 description 8
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 239000008213 purified water Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 5
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 5
- 239000004327 boric acid Substances 0.000 description 5
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- 229960000281 trometamol Drugs 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000002736 nonionic surfactant Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- AYRVGWHSXIMRAB-UHFFFAOYSA-M sodium acetate trihydrate Chemical compound O.O.O.[Na+].CC([O-])=O AYRVGWHSXIMRAB-UHFFFAOYSA-M 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- WGJJROVFWIXTPA-OALUTQOASA-N prostanoic acid Chemical compound CCCCCCCC[C@H]1CCC[C@@H]1CCCCCCC(O)=O WGJJROVFWIXTPA-OALUTQOASA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- HLWRUJAIJJEZDL-UHFFFAOYSA-M sodium;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetate Chemical compound [Na+].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC([O-])=O HLWRUJAIJJEZDL-UHFFFAOYSA-M 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 229950008081 unoprostone isopropyl Drugs 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 102100031083 Uteroglobin Human genes 0.000 description 1
- 108090000203 Uteroglobin Proteins 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229960001716 benzalkonium Drugs 0.000 description 1
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- GGXICVAJURFBLW-RDSJPUOVSA-N propan-2-yl (e)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(3r)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate Chemical compound CC(C)OC(=O)CCC\C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-RDSJPUOVSA-N 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000012087 reference standard solution Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HRQDCDQDOPSGBR-UHFFFAOYSA-M sodium;octane-1-sulfonate Chemical compound [Na+].CCCCCCCCS([O-])(=O)=O HRQDCDQDOPSGBR-UHFFFAOYSA-M 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Pregnancy & Childbirth (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9278698P | 1998-07-14 | 1998-07-14 | |
| US60/092,786 | 1998-07-14 | ||
| PCT/US1999/013276 WO2000003736A1 (en) | 1998-07-14 | 1999-06-15 | Prostaglandin product |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010017455A Division JP2010100652A (ja) | 1998-07-14 | 2010-01-28 | プロスタグランジン製品 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002520368A true JP2002520368A (ja) | 2002-07-09 |
| JP2002520368A5 JP2002520368A5 (https=) | 2010-04-02 |
Family
ID=22235155
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000559870A Pending JP2002520368A (ja) | 1998-07-14 | 1999-06-15 | プロスタグランジン製品 |
| JP2010017455A Pending JP2010100652A (ja) | 1998-07-14 | 2010-01-28 | プロスタグランジン製品 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010017455A Pending JP2010100652A (ja) | 1998-07-14 | 2010-01-28 | プロスタグランジン製品 |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1011728B1 (https=) |
| JP (2) | JP2002520368A (https=) |
| KR (1) | KR20010021835A (https=) |
| CN (1) | CN1146423C (https=) |
| AR (1) | AR019773A1 (https=) |
| AT (1) | ATE285795T1 (https=) |
| AU (1) | AU743607B2 (https=) |
| BR (1) | BR9906597A (https=) |
| CA (1) | CA2295512C (https=) |
| DE (1) | DE69922916T2 (https=) |
| ES (1) | ES2234270T3 (https=) |
| PT (1) | PT1011728E (https=) |
| TW (1) | TW585769B (https=) |
| WO (1) | WO2000003736A1 (https=) |
| ZA (1) | ZA997794B (https=) |
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005011704A1 (ja) * | 2003-07-31 | 2005-02-10 | Santen Pharmaceutical Co., Ltd. | プロスタグランジン含有製品 |
| WO2006068266A1 (ja) * | 2004-12-24 | 2006-06-29 | Santen Pharmaceutical Co., Ltd. | プロスタグランジンＦ２ａ誘導体含有製品 |
| JP2006187602A (ja) * | 2004-12-09 | 2006-07-20 | Santen Pharmaceut Co Ltd | 分子内にフッ素原子を有するプロスタグランジン含有製品 |
| JP2006198400A (ja) * | 2004-12-24 | 2006-08-03 | Santen Pharmaceut Co Ltd | プロスタグランジンＦ２ａ誘導体含有製品 |
| WO2007015510A1 (ja) * | 2005-08-02 | 2007-02-08 | Santen Pharmaceutical Co., Ltd. | 熱的に不安定な薬物の分解抑制方法 |
| JP2007063265A (ja) * | 2005-08-02 | 2007-03-15 | Santen Pharmaceut Co Ltd | 熱的に不安定な薬物の分解抑制方法 |
| WO2008096804A1 (ja) | 2007-02-07 | 2008-08-14 | Teika Pharmaceutical Co., Ltd. | ラタノプロスト含有点眼剤 |
| WO2009028674A1 (ja) * | 2007-08-29 | 2009-03-05 | Wakamoto Pharmaceutical Co., Ltd. | ラタノプロスト含有水性医薬組成物 |
| JPWO2007105691A1 (ja) * | 2006-03-13 | 2009-07-30 | 株式会社アールテック・ウエノ | 水性組成物 |
| JP2009256281A (ja) * | 2008-04-21 | 2009-11-05 | Teika Seiyaku Kk | イソプロピルウノプロストン含有点眼剤組成物 |
| JP2010100652A (ja) * | 1998-07-14 | 2010-05-06 | Alcon Lab Inc | プロスタグランジン製品 |
| JP4563636B2 (ja) * | 1999-09-10 | 2010-10-13 | 大正製薬株式会社 | プロスタグランジン誘導体 |
| WO2011027778A1 (ja) * | 2009-09-01 | 2011-03-10 | 株式会社アールテック・ウエノ | 高眼圧症および緑内障処置のための眼局所投与用組成物 |
| JP2011508724A (ja) * | 2007-10-16 | 2011-03-17 | サン、ファーマ、アドバンスト、リサーチ、カンパニー、リミテッド | 新規眼科用組成物 |
| WO2011034192A1 (ja) | 2009-09-17 | 2011-03-24 | 千寿製薬株式会社 | ラタノプロストを含有する水性点眼剤、並びにラタノプロストの樹脂への吸着の抑制方法 |
| JP2011514384A (ja) * | 2008-03-17 | 2011-05-06 | アルコン リサーチ， リミテッド | 望ましい生物学的利用能を有する薬学的組成物 |
| JP2011521943A (ja) * | 2008-05-30 | 2011-07-28 | 参天製薬株式会社 | 高眼圧症及び緑内障を治療するための方法及び組成物 |
| JP2012516187A (ja) * | 2009-02-20 | 2012-07-19 | マイクロ ラブズ リミテッド | 貯蔵安定性プロスタグランジン製品 |
| JP2019526629A (ja) * | 2016-08-31 | 2019-09-19 | アエリエ ファーマシューティカルズ インコーポレイテッド | 眼科用組成物 |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4834224B2 (ja) | 1999-03-05 | 2011-12-14 | デューク ユニバーシティ | Ｃ１６不飽和ｆｐ−選択的プロスタグランジン類縁体 |
| US6894175B1 (en) | 1999-08-04 | 2005-05-17 | The Procter & Gamble Company | 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use |
| US20020172693A1 (en) | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
| US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| US20020037914A1 (en) | 2000-03-31 | 2002-03-28 | Delong Mitchell Anthony | Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins |
| CA2422031C (en) * | 2000-09-13 | 2011-11-15 | Santen Pharmaceutical Co., Ltd. | Ophthalmic solutions comprising difluoroprostaglandin f2 alpha |
| WO2002022106A2 (en) * | 2000-09-14 | 2002-03-21 | Novartis Ag | Stable ophthalmic preparation |
| EP1486192A4 (en) * | 2002-03-18 | 2010-07-14 | Santen Pharmaceutical Co Ltd | HIGH-TEMPERATURE-STERILIZABLE INSTILLER |
| DK1532981T3 (da) * | 2002-08-23 | 2008-01-28 | Santen Pharmaceutical Co Ltd | Stabile öjendråber, der indeholder latanoprost som den aktive bestanddel |
| CN105566192B (zh) * | 2006-10-02 | 2019-01-22 | 于崇曦 | 具有快速皮肤穿透速度的带正电荷的水溶性的前列腺素及相关化合物的前药 |
| US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
| US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
| US20100087540A1 (en) * | 2008-10-07 | 2010-04-08 | R-Tech Ueno, Ltd. | Pharmaceutical composition |
| EP3053913B1 (en) | 2009-05-01 | 2018-03-07 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
| DE102009021372A1 (de) * | 2009-05-14 | 2010-11-18 | Ursapharm Arzneimittel Gmbh | Phosphatfreie pharmazeutische Zusammensetzung zur Glaukombehandlung |
| US8658676B2 (en) | 2010-10-12 | 2014-02-25 | The Medicines Company | Clevidipine emulsion formulations containing antimicrobial agents |
| EP2627173B2 (en) * | 2010-10-12 | 2018-07-04 | Chiesi Farmaceutici S.p.A. | Clevidipine emulsion formulations containing antimicrobial agents |
| EP2452669A1 (en) | 2010-10-29 | 2012-05-16 | Omnivision GmbH | Ophthalmic composition |
| EP2567689A1 (en) | 2011-09-12 | 2013-03-13 | Visiotact Pharma | Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid |
| DK3811943T3 (da) | 2013-03-15 | 2023-04-03 | Aerie Pharmaceuticals Inc | Forbindelse til anvendelse til behandling af øjenlidelser |
| ES2953346T3 (es) * | 2014-01-10 | 2023-11-10 | Santen Pharmaceutical Co Ltd | Composición farmacéutica que contiene un compuesto de ácido piridilaminoacético y aceite de ricino polioxietilenado |
| BR112016015909B1 (pt) | 2014-01-10 | 2020-09-29 | Santen Pharmaceutical Co., Ltd. | Composição farmacêutica contendo composto de ácido piridilaminoacético |
| JP5951921B1 (ja) * | 2014-12-12 | 2016-07-13 | 興和株式会社 | 組成物 |
| US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
| KR20190135027A (ko) | 2017-03-31 | 2019-12-05 | 에어리 파마슈티컬즈, 인코포레이티드 | 아릴 시클로프로필-아미노-이소퀴놀리닐 아미드 화합물 |
| AU2019337703B2 (en) | 2018-09-14 | 2023-02-02 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
| KR102756146B1 (ko) * | 2019-06-28 | 2025-01-17 | 한미약품 주식회사 | 저장 안정성이 개선된 라타노프로스트 함유 점안제 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62292719A (ja) * | 1986-06-12 | 1987-12-19 | Kaken Pharmaceut Co Ltd | 外用澄明水溶性製剤 |
| JPS6366122A (ja) * | 1986-03-13 | 1988-03-24 | ザ・トラステイ−ズ・オブ・コロンビア・ユニヴア−シテイ・イン・ザ・シテイ・オブ・ニユ−・ヨ−ク | 緑内障の局所治療用組成物 |
| JPH0228112A (ja) * | 1988-04-21 | 1990-01-30 | Kaken Pharmaceut Co Ltd | 点眼用眼圧調整剤 |
| JPH09124484A (ja) * | 1995-10-27 | 1997-05-13 | Schering Purau Kk | 点眼剤 |
| WO1997029752A1 (en) * | 1994-12-22 | 1997-08-21 | Alcon Laboratories, Inc. | Storage-stable prostaglandin compositions |
| JPH10101863A (ja) * | 1996-09-30 | 1998-04-21 | Nippon Zeon Co Ltd | 成形材料 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA88963B (en) * | 1987-02-27 | 1989-11-29 | Allergan Inc | Prostaglandins useful for lowering intraocular pressure |
| JP3256997B2 (ja) * | 1990-08-30 | 2002-02-18 | 千寿製薬株式会社 | 安定な水性製剤 |
| US5425480A (en) * | 1992-12-17 | 1995-06-20 | Ryder International Corporation | Dose dispenser having a molded plastic housing with a cavity and a metallic foil wall covering the cavity |
| WO2000003736A1 (en) * | 1998-07-14 | 2000-01-27 | Alcon Laboratories, Inc. | Prostaglandin product |
-
1999
- 1999-06-15 WO PCT/US1999/013276 patent/WO2000003736A1/en not_active Ceased
- 1999-06-15 CA CA002295512A patent/CA2295512C/en not_active Expired - Fee Related
- 1999-06-15 AT AT99931790T patent/ATE285795T1/de active
- 1999-06-15 AU AU48220/99A patent/AU743607B2/en not_active Ceased
- 1999-06-15 PT PT99931790T patent/PT1011728E/pt unknown
- 1999-06-15 EP EP99931790A patent/EP1011728B1/en not_active Revoked
- 1999-06-15 JP JP2000559870A patent/JP2002520368A/ja active Pending
- 1999-06-15 CN CNB998007757A patent/CN1146423C/zh not_active Ceased
- 1999-06-15 ES ES99931790T patent/ES2234270T3/es not_active Expired - Lifetime
- 1999-06-15 BR BR9906597-5A patent/BR9906597A/pt not_active Application Discontinuation
- 1999-06-15 DE DE69922916T patent/DE69922916T2/de not_active Expired - Lifetime
- 1999-06-15 KR KR1020007000399A patent/KR20010021835A/ko not_active Ceased
- 1999-06-22 TW TW088110467A patent/TW585769B/zh not_active IP Right Cessation
- 1999-07-13 AR ARP990103414A patent/AR019773A1/es unknown
- 1999-12-21 ZA ZA9907794A patent/ZA997794B/xx unknown
-
2010
- 2010-01-28 JP JP2010017455A patent/JP2010100652A/ja active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6366122A (ja) * | 1986-03-13 | 1988-03-24 | ザ・トラステイ−ズ・オブ・コロンビア・ユニヴア−シテイ・イン・ザ・シテイ・オブ・ニユ−・ヨ−ク | 緑内障の局所治療用組成物 |
| JPS62292719A (ja) * | 1986-06-12 | 1987-12-19 | Kaken Pharmaceut Co Ltd | 外用澄明水溶性製剤 |
| JPH0228112A (ja) * | 1988-04-21 | 1990-01-30 | Kaken Pharmaceut Co Ltd | 点眼用眼圧調整剤 |
| WO1997029752A1 (en) * | 1994-12-22 | 1997-08-21 | Alcon Laboratories, Inc. | Storage-stable prostaglandin compositions |
| JPH09124484A (ja) * | 1995-10-27 | 1997-05-13 | Schering Purau Kk | 点眼剤 |
| JPH10101863A (ja) * | 1996-09-30 | 1998-04-21 | Nippon Zeon Co Ltd | 成形材料 |
Cited By (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010100652A (ja) * | 1998-07-14 | 2010-05-06 | Alcon Lab Inc | プロスタグランジン製品 |
| JP4563636B2 (ja) * | 1999-09-10 | 2010-10-13 | 大正製薬株式会社 | プロスタグランジン誘導体 |
| WO2005011704A1 (ja) * | 2003-07-31 | 2005-02-10 | Santen Pharmaceutical Co., Ltd. | プロスタグランジン含有製品 |
| JP2006187602A (ja) * | 2004-12-09 | 2006-07-20 | Santen Pharmaceut Co Ltd | 分子内にフッ素原子を有するプロスタグランジン含有製品 |
| JP2011063625A (ja) * | 2004-12-09 | 2011-03-31 | Santen Pharmaceut Co Ltd | 分子内にフッ素原子を有するプロスタグランジン含有製品 |
| WO2006068266A1 (ja) * | 2004-12-24 | 2006-06-29 | Santen Pharmaceutical Co., Ltd. | プロスタグランジンＦ２ａ誘導体含有製品 |
| JP2006198400A (ja) * | 2004-12-24 | 2006-08-03 | Santen Pharmaceut Co Ltd | プロスタグランジンＦ２ａ誘導体含有製品 |
| RU2391983C2 (ru) * | 2004-12-24 | 2010-06-20 | Сантен Фармасьютикал Ко., Лтд | Продукт, содержащий производное простагландина f2 альфа |
| WO2007015510A1 (ja) * | 2005-08-02 | 2007-02-08 | Santen Pharmaceutical Co., Ltd. | 熱的に不安定な薬物の分解抑制方法 |
| JP2007063265A (ja) * | 2005-08-02 | 2007-03-15 | Santen Pharmaceut Co Ltd | 熱的に不安定な薬物の分解抑制方法 |
| JP2014111661A (ja) * | 2006-03-13 | 2014-06-19 | R Tec Ueno:Kk | 水性組成物 |
| JPWO2007105691A1 (ja) * | 2006-03-13 | 2009-07-30 | 株式会社アールテック・ウエノ | 水性組成物 |
| JP2012167095A (ja) * | 2006-03-13 | 2012-09-06 | R Tec Ueno:Kk | 水性組成物 |
| WO2008096804A1 (ja) | 2007-02-07 | 2008-08-14 | Teika Pharmaceutical Co., Ltd. | ラタノプロスト含有点眼剤 |
| WO2009028674A1 (ja) * | 2007-08-29 | 2009-03-05 | Wakamoto Pharmaceutical Co., Ltd. | ラタノプロスト含有水性医薬組成物 |
| US9456980B2 (en) | 2007-08-29 | 2016-10-04 | Wakamoto Pharmaceutical Co., Ltd. | Latanoprost-containing aqueous pharmaceutical composition |
| JP2011508724A (ja) * | 2007-10-16 | 2011-03-17 | サン、ファーマ、アドバンスト、リサーチ、カンパニー、リミテッド | 新規眼科用組成物 |
| JP2011514384A (ja) * | 2008-03-17 | 2011-05-06 | アルコン リサーチ， リミテッド | 望ましい生物学的利用能を有する薬学的組成物 |
| JP2009256281A (ja) * | 2008-04-21 | 2009-11-05 | Teika Seiyaku Kk | イソプロピルウノプロストン含有点眼剤組成物 |
| US10864159B2 (en) | 2008-05-30 | 2020-12-15 | Santen Pharmaceutical Co., Ltd. | Method and composition for treating ocular hypertension and glaucoma |
| JP2014133765A (ja) * | 2008-05-30 | 2014-07-24 | Santen Pharmaceut Co Ltd | 高眼圧症及び緑内障を治療するための方法及び組成物 |
| JP2011521943A (ja) * | 2008-05-30 | 2011-07-28 | 参天製薬株式会社 | 高眼圧症及び緑内障を治療するための方法及び組成物 |
| US9999593B2 (en) | 2008-05-30 | 2018-06-19 | Santen Pharmaceutical Co., Ltd. | Method and composition for treating ocular hypertension and glaucoma |
| JP2012516187A (ja) * | 2009-02-20 | 2012-07-19 | マイクロ ラブズ リミテッド | 貯蔵安定性プロスタグランジン製品 |
| WO2011027778A1 (ja) * | 2009-09-01 | 2011-03-10 | 株式会社アールテック・ウエノ | 高眼圧症および緑内障処置のための眼局所投与用組成物 |
| WO2011034192A1 (ja) | 2009-09-17 | 2011-03-24 | 千寿製薬株式会社 | ラタノプロストを含有する水性点眼剤、並びにラタノプロストの樹脂への吸着の抑制方法 |
| JP2019526629A (ja) * | 2016-08-31 | 2019-09-19 | アエリエ ファーマシューティカルズ インコーポレイテッド | 眼科用組成物 |
| JP2020172524A (ja) * | 2016-08-31 | 2020-10-22 | アエリエ ファーマシューティカルズ インコーポレイテッド | 製剤 |
| JP2021165285A (ja) * | 2016-08-31 | 2021-10-14 | アエリエ ファーマシューティカルズ インコーポレイテッド | 眼科用組成物 |
| JP7083005B2 (ja) | 2016-08-31 | 2022-06-09 | アエリエ ファーマシューティカルズ インコーポレイテッド | 眼科用組成物 |
| JP7192049B2 (ja) | 2016-08-31 | 2022-12-19 | アエリエ ファーマシューティカルズ インコーポレイテッド | 眼科用組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU743607B2 (en) | 2002-01-31 |
| HK1028563A1 (en) | 2001-02-23 |
| ZA997794B (en) | 2001-01-02 |
| KR20010021835A (ko) | 2001-03-15 |
| CN1146423C (zh) | 2004-04-21 |
| ES2234270T3 (es) | 2005-06-16 |
| CA2295512C (en) | 2009-05-26 |
| DE69922916T2 (de) | 2005-06-09 |
| DE69922916D1 (de) | 2005-02-03 |
| EP1011728B1 (en) | 2004-12-29 |
| BR9906597A (pt) | 2000-07-18 |
| ATE285795T1 (de) | 2005-01-15 |
| JP2010100652A (ja) | 2010-05-06 |
| CA2295512A1 (en) | 2000-01-14 |
| EP1011728A1 (en) | 2000-06-28 |
| WO2000003736A1 (en) | 2000-01-27 |
| TW585769B (en) | 2004-05-01 |
| AU4822099A (en) | 2000-02-07 |
| CN1272063A (zh) | 2000-11-01 |
| PT1011728E (pt) | 2005-03-31 |
| AR019773A1 (es) | 2002-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002520368A (ja) | プロスタグランジン製品 | |
| US6235781B1 (en) | Prostaglandin product | |
| EP0812198B1 (en) | Stabilization of prostaglandin compositions | |
| US6011062A (en) | Storage-stable prostaglandin compositions | |
| US9539262B2 (en) | Ophthalmic composition comprising a prostaglandin | |
| MXPA96003560A (en) | Compositions of stable prostaglandines enalmacenamie | |
| EP2398443A2 (en) | Storage stable prostaglandin product | |
| EP2566453A1 (en) | Novel ophthalmic compositions | |
| DE DK et al. | POLYPROPYLENBASIERTE BEHÄLTER FÜR PROSTAGLANDIN-ENTHALTENDE PRODUKTE RECIPIENTS A BASE DE POLYPROPYLENE POUR DES PRODUITS DE PROSTAGLANDINE | |
| HK1028563B (en) | Polypropylene containers for prostaglandin products | |
| MXPA00002550A (es) | Producto de prostaglandina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060519 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060519 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091124 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20100128 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100604 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100930 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20101208 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20110107 |